Repros Therapeutics — Investor Presentation (August 2016)
34 slides from Repros Therapeutics's investor presentation, Aug 18, 2016
Slide 1: Repros Therapeutics
Repros Therapeutics Development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
Slide 2: Repros Disclaimer
Repros Disclaimer Any statements made by Repros Therapeutics Inc . (“Repros” or the “Company”) that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
Slide 3: Building Shareholder Value
Building Shareholder Value • Development of differentiated oral, NCE, both with patent lives to mid 2020’s, therapies to treat significant unmet medical needs for male and female uro - genital disorders – Female indications targeted with Proellex ( telapristone acetate) • Symptomatic uterine fibroid
Slide 4: Delivering the Value
Delivering the Value • Cost effective clinical development – Internal clinical/regulatory team led by experienced staff reduces capital requirements • Proellex in Phase 2 for both fibroids and endometriosis • Enclomiphene NDA on file (CRL received Nov. 2015) and in Phase 2 for secondary hypogonadism
Slide 5: Company Board of Directors and Management
Company Board of Directors and Management • Non Employee Board of Directors – Patrick Fourteau (Chairman) – Dan Cain – Nola Masterson – Saira Ramasastry – Michael Wyllie, Ph.D., DSC • Management – Joseph Podolski, CEO – Kathi Anderson, CFO – Jaye Thompson Ph.D., Sr. V.P. Clinical and Regulatory – Jo
Slide 6: Proellex
Proellex Addressing significant unmet female reproductive disorders
Slide 7: Uterine Fibroids & Endometriosis
Uterine Fibroids & Endometriosis Poor therapeutic options for debilitating female disorders experienced by women in the prime of their life • Benign, monoclonal, hormone sensitive, smooth muscle tumors of the uterus • Most common tumor of the female reproductive tract – Heavy bleeding / anemia – Abd
Slide 8: How Antiprogestins Like Proellex Work
O O OMe N OAc CH 3 H 3 C How Antiprogestins Like Proellex Work Antiprogestins • Selectively block progesterone activity • Allow tonic hormone secretions – Alleviate negative side effects of GnRHa • Potential for chronic use Different than GnRH agonists and antagonists. These agents: • Block hypothal
Slide 9: Proellex Evolution of Lead Compound
PROELLEX EVOLUTION OF LEAD COMPOUND O CH 3 O OMe N OAc CH 3 H 3 C 44 Analogues Synthesized to Date O CH 3 OH 3 C N OAc CH 3 H 3 C CDB - 2914 ( Ulipristal Acetate) • NIH precursor to Repros class • Allergan marketing molecule ( Esmya ) in Europe for treatment of uterine fibroids CDB - 4124 Proellex (
Slide 10: An Effective Dose of Proellex Stops Menstruation in Majority of Women
An Effective Dose of Proellex Stops Menstruation in Majority of Women Induction of amenorrhea relieves key symptoms of uterine fibroids and endometriosis 0 10 20 30 40 50 60 70 80 90 100 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg % of Women with Induced Amenorrhea Proellex induced amenorrhea (no ovulatio
Slide 11: Impact of Proellex Treatment on Uterine Fibroids and Endometriosis
Impact of Proellex Treatment on Uterine Fibroids and Endometriosis -10 0 10 20 30 40 50 60 70 80 90 % Amenorrhea % Reduction in Fibroid Volume % Effects of 12 mg Proellex after 18 weeks of continuous treatment of severe uterine fibroids 12 mg Proellex Placebo Fibroids continue to grow in placebo gro
Slide 12: Impact of Proellex Treatment on Pain Symptoms of Severe Endometriosis
Impact of Proellex Treatment in Women Experiencing the Pain Symptoms Associated with Severe Endometriosis (interim findings) 0 5 10 15 20 25 30 35 0 2 4 6 8 10 12 14 Baseline 18 weeks Number of Analgesics Used During 28 Day Menstrual Cycle Days of Menstrual Pain Changes in Days of Menstrual Pain and
Slide 13: Key Advantage of Proellex Over Other Antiprogestins in Development
All other antiprogestins in development require off - drug - interval after 12 weeks of treatment Key Advantage of Proellex Over Other Antiprogestins in Development Proliferative Disordered Proliferative Benign Endometrial Hyperplasia Mutter et al, 2007 12.5mg Proellex No hyperplasia Estrogen over T
Slide 14: Proellex Clinical Goals
Proellex Clinical Goals • Confirm Phase 3 requirements with FDA • Uterine Fibroids: Fourth Quarter 2016 • Endometriosis: First Quarter 2017 • Completed Proellex NDA components • Pre - clinical complete (including 2 carcinogenicity studies) • Manufacturing complete (API sourced, stable final drug pro
Slide 15: Proellex Summary
Proellex Summary • Potential Proellex market opportunity > $1 Billion for Fibroids and Endometriosis • Rigorous clinical program working to move into Phase 3 • Significant clinical advantages identified against GnRH agonists/antagonists • Longer symptom relief established against other approved or i
Slide 16: Encyzix (enclomiphene)
Encyzix ( enclomiphene ) Rational treatment for secondary hypogonadism
Slide 17: Secondary Hypogonadism
Secondary Hypogonadism The Leading Cause of Low T and Usage of T Replacement Therapies It is not age related! The vast majority of hypogonadal men are secondary and suffer from the disorder due to being overweight or obese EMAS data suggests the incidence of secondary hypogonadism is nearly 10X grea
Slide 18: Secondary Hypogonadism at Baseline
Institute of Human Development Centre for Endocrinology & Diabetes Manchester Academic Health Sciences Centre Secondary Hypogonadism at Baseline Age (years) BMI ≥ 25 - <30 kg/m2 BMI ≥ 30 kg/m2 Smoking (current) Alcohol (frequent) Morbidity ( ≥ 1) 0 5 10 15 *** *** * Poor morning erection Sexual thou
Slide 19: Current Group of Men Seeking Treatment for Hypogonadism
So What Do We Know About the Current Group of Men Seeking Treatment for Hypogonadism? • The majority are secondary hypogonadal and are fertile • Confirmatory diagnosis not practiced in the US • No studies conducted by hormone replacement sponsors to assess impact on spermatogenesis • “But these men
Slide 20: Obesity Related Hypogonadism is a Reversible Disorder
Camacho et al. European Journal of Endocrinology 2013 Obesity Related Hypogonadism is a Reversible Disorder Treatment with Exogenous T “May require lifelong therapy” (Bayer abstract quote) (a) Total testosterone ( nmol I - 1 ) in hypogonadal men with continuous (n=115) and interrupted (n=147) testos
Slide 21: Size of Overweight and Obese US Population
Size of Overweight and Obese US Population It is more than a sex issue 83,740,000 Males Age 20 - 60 58,620,000 Overweight or Obese 28,470,000 Metabolic Syndrome 1,700,000 Symptomatic (libido, etc.) Overweight or Obese Estimates based on CDC, EMAS and Sponsor Data
Slide 22: How Enclomiphene Works
How Enclomiphene Works Enclomiphene blocks estrogen at the level of the H - P axis increasing LH levels which in turn increases endogenous production of T 0 1 2 3 4 5 6 7 Enclomiphene LH Androgel LH Median LH ( mIU /mL) Impact on LH in 16 Wk Study ZA - 304 Baseline End of Study 0 50 100 150 200 250
Slide 23: Proof of Concept Diet & Exercise Study in Obese Hypogonadal Men
Phase 2 Proof of Concept “Diet & Exercise” Study in Obese Hypogonadal Men - Baseline Findings Screen 98 to enroll 50 15 Month Study • Enrollment (n=50 in 5 weeks @ 5 sites) • Demographics ( stdev ) – Age: 43.3 (9.2) – BMI: 36.8 (3.2) – Waist: 46.9” (4.1) – % Body Fat: 38.1 (5.2) • Hormonal Status –
Slide 24: Interim Month Data
Interim 6 Month Data (CLEIA assay) ZA - 205 30 31 32 33 34 35 36 37 38 39 Bl 3 mo 6 mo 9 mo 12 mo 15mo BMI BMI Over Time 12.5 mg 25 mg pbo 0 100 200 300 400 500 600 700 Scr BL 3 mo 6 mo 9 mo 12 mo 15 mo Morning T (ng/ dL ) Morning T Over Time 12.5 mg 25 mg pbo Commercial diet ends at 6 months. Perso
Slide 25: Interim Month Data: Lean Mass, LCMS T & Free T
Interim 6 Month Data Lean Mass, LCMS T & Free T 63.5 64 64.5 65 65.5 66 66.5 67 67.5 68 68.5 Baseline 6 Month 12 Month 15 Month Lean Mass by DXA (kg) 12.5 mg 25 mg Placebo 0 20 40 60 80 100 120 140 160 180 0 100 200 300 400 500 600 700 800 900 1000 Baseline 6 Month 12 Month 15 Month Free T ( pg /mL)
Slide 26: Enclomiphene vs TRT
Enclomiphene vs TRT TRT Enclomiphene Administration Topical/IM Oral Transference risk (topical) Yes No Supranormal T levels Yes No Suppressed spermatogenesis Yes No Suppressed testicular function Yes No Testi s atrophy Yes No Extensively studied No Yes
Slide 27: Enclomiphene Development Status
Enclomiphene Development Status • Central EU filing ongoing – Anticipated marketing authorization Q4 - ’17 – Treatment for secondary hypogonadism • FDA Complete Response to NDA – Must provide evidence of clinical benefit – We expect FDA to hold advisory committee meeting on secondary hypogonadism •
Slide 28: Repros Late Stage Assets
Repros Late Stage Assets Repros seeking regional or global development/commercialization partners
Slide 29: Financial Summary
Financial Summary • Cash and equivalents: (unaudited June 30, 2016) $12.5 M • Cash used in 2016 through June 30, 2016 : $8.9 M • Cash runway: Q1 2017 • Current shares outstanding: 24.3 M shares
Slide 30: Appendix: Board of Directors and Management
Appendix: Board of Directors and Management • Board of Directors – Patrick Fourteau (Chairman) Mr. Fourteau was elected a director, serving as chair of the board, in May 2016. Mr . Fourteau currently serves as the Chief Executive Officer and a member of the Board of Directors of New Haven Pharmaceut
Slide 31: Appendix: Board of Directors and Management (cont.)
Appendix: Board of Directors and Management • Board of Directors ( con’t .) – Nola Masterson Ms. Masterson is Managing Director of Science Futures Management Co. LLC, an investment and advisory service business specializing in biopharmaceuticals, NGS and genomic tools and diagnostics. Ms. Masterson
Slide 32: Appendix: Board of Directors and Management (cont.)
Appendix: Board of Directors and Management • Board of Directors ( con’t .) – Michael Wyllie, Ph.D., DSC Dr. Wyllie has over 30 years of experience in senior management positions in the pharmaceutical industry. He is a director and founder of Global Pharma Consulting and is a graduate of the Univers
Slide 33: Appendix: Board of Directors and Management
Appendix: Board of Directors and Management • Management – Joseph Podolski, President and CEO Mr. Podolski has served as Chief Executive Officer and as a director since 1992. He joined us in 1989 as Vice President of Operations and is the named inventor on the majority of the Company’s patents for b
Slide 34: Appendix: Board of Directors and Management (cont.)
Appendix: Board of Directors and Management • Management ( con’t .) – Jaye Thompson, Ph.D., Sr. V.P., Clinical and Regulatory Dr. Thompson was the Senior Vice President for Regulatory Affairs and Emerging Biotechnologies at inVentiv Clinical Solutions, LLC, a wholly - owned subsidiary of inVentiv He
Repros Therapeutics — Investor Presentation (August 2016) on 6ix